Elisabeth Niemoeller

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin

Matthew C. Riddle, Ronnie Aronson, Philip Home et al. · Diabetes Care · 2013 · 285 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

Julio Rosenstock, Ronnie Aronson, George Grunberger et al. · Diabetes Care · 2016 · 268 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Vanita R. Aroda, Julio Rosenstock, Carol Wysham et al. · Diabetes Care · 2016 · 256 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Randomized, double‐blind, placebo‐controlled trial of the once‐daily <scp>GLP</scp> ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( <scp>GetGoal</scp> ‐L‐Asia)

Yutaka Seino, Kyung Wan Min, Elisabeth Niemoeller et al. · Diabetes Obesity and Metabolism · 2012 · 253 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes

Eleanor L. Ramos, Colin Dayan, Lucienne Chatenoud et al. · New England Journal of Medicine · 2023 · 234 citations · Full text

Pharmacy, Endocrinology, Pharmacotherapy +17